Role of PTPN2/22 polymorphisms in pathophysiology of Crohn’s disease

Table 2 MAP IS900 nPCR presence and correlation with PTPN2:rs478582/PTPN22:rs2476601 in clinical subjects

MAP presence
	Healthy	CD	OR (95%CI)
Overall	4/48 (9.33%)	43/70 (61.4%)a	17.5 (5.65–54.3)a
rs478582
TT	2/17 (11.8%)	6/12 (50%)a	7.5 (1.17-48.2)a
TC	0/22 (0%)	25/37 (67.6%)	91.8 (5.14-1604.3)a
CC	2/8 (25%)	9/19 (47.4%)	2.7 (0.43-16.9)
TC + CC	2/30 (6.67%)	34/56 (60.7%)a	21.6 (4.68-100.1)a
rs2476601
GG	4/59 (6.78%)	33/59 (55.9%)a	17.6 (5.59-54.4)a
GA	0/4 (0%)	3/10 (30.0%)	4.2 (0.17-101.5)
AA	0/1 (0%)	0/1 (0%)	1.00 (0.02-92.4)
GA + AA	0/5 (0%)	3/11 (27.3%)	4.53 (0.19-105.8)
Haplotypes
T-G	2/15 (13.3%)	5/10 (50.0%)a	6.5 (0.94-45.1)a
C-G	2/29 (6.90%)	31/46 (67.4%)a	30.0 (6.3-142.6)a
T-A	0/2 (0%)	1/2 (50.0%)	5.00 (0.11-220.6)
C-A	0/2 (0%)	3/9 (33.3%)	2.69 (0.1-73.2)

^aP < 0.05 vs healthy.